Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment.
Level 2 - randomized trial
Secondary interaction analysis of an individual randomized controlled trial
PubMed 26757190 · doi:10.3233/JAD-150777
What was done
In a secondary analysis of the VITACOG trial, 266 participants aged 70 years or older with mild cognitive impairment were randomized to receive daily B vitamins (folic acid, vitamin B6, and vitamin B12) or placebo for 2 years. Authors evaluated whether baseline plasma concentrations of total omega-3 fatty acids (specifically docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) modified the effect of B vitamin treatment on verbal delayed recall, global cognition, and Clinical Dementia Rating (CDR) sum-of-boxes scores.
What was found
B vitamin benefits were dependent on baseline omega-3 levels: - Final scores for verbal delayed recall, global cognition, and CDR sum-of-boxes improved in the B vitamin group as baseline omega-3 concentrations increased, while scores in the placebo group remained unchanged across omega-3 concentrations. - Among individuals with good baseline omega-3 status, 33% of those receiving B vitamins had global CDR scores >0 compared with 59% in the placebo group. - Higher baseline DHA concentrations alone significantly enhanced B vitamin effects across all three measures, whereas EPA appeared less effective. - In participants with low omega-3 concentrations, B vitamin treatment showed no effect on cognitive decline.
Why it matters
This study shows that B vitamin efficacy for slowing cognitive decline in mild cognitive impairment depends on adequate baseline omega-3 fatty acid status, particularly DHA. It provides a rationale for testing combined B vitamin and omega-3 fatty acid supplementation in future trials.
Limits
This was an exploratory post-hoc subgroup analysis rather than a trial directly randomizing omega-3 supplementation. Exact confidence intervals, test statistics, and p-values were not reported in the abstract, and findings are restricted to adults aged 70 and older with mild cognitive impairment.